ArticleNPJ precision oncology2026
An interpretable deep learning model for predicting endometrial cancer molecular subtypes from H&E-stained slides.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Artificial Intelligence and Digital Pathology for Molecular Classification of Endometrial Cancer.International journal of molecular sciences · 2026Review
- Artificial intelligence as a pragmatic adjunct to molecular classification in endometrial cancer.Ewha medical journal · 2026Article
- Integrating artificial intelligence and multi-omics data for precision oncology in endometrial cancer: a narrative review.Functional & integrative genomics · 2026Review
- Digital pathology and artificial intelligence in breast and gynecologic oncology: from molecular prediction to multimodal integration.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
The molecular subtype of endometrial cancer is important for predicting prognosis and treatment effectiveness. This study aimed to develop an interpretable deep learning model based on H&E-stained whole slide images (WSIs) to predict the molecular subtype of endometrial cancer. Data from the Fudan cohort (n = 364) were used to train an end-to-end prediction network for identifying four molecular subtypes. Two external cohorts-the TCGA (n = 296) and Suzhou (n = 36)-were used to validate model generalizability and potential clinical applicability. We further assessed the correlation between histological and molecular features at both the macro- (WSI) and micro- (patch) levels. The network achieved a macro-average area under the receiver operating characteristic curve (AUROC) of 0.867 (95% CI: 0.823-0.911) in 5-fold cross-validation. The class-wise AUROCs were 0.846 (95% CI: 0.798-0.894) for the microsatellite instability-high (MSI-H) subtype, 0.876 (95% CI: 0.831-0.921) for the nonspecific molecular profile (NSMP) subtype, 0.910 (95% CI: 0.818-1.000) for the p53-abnormal (p53abn) subtype, and 0.835 (95% CI: 0.784-0.886) for the POLE-mutated (POLEmut) subtype. Morphological analysis revealed that MSI-H-subtype tumors exhibited increased stromal lymphocytic infiltration; POLEmut tumors showed higher heterogeneity, solid growth patterns, and elevated tumor grade; p53abn tumors were characterized by papillary growth and serous-like features; while NSMP tumors demonstrated high stromal cellularity. This method provides an accurate and interpretable tool for molecular subtype prediction, offering a theoretical basis for future individualized treatment strategies in endometrial cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.